The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 4×
“These findings, which confirmed similar findings reported with dapagliflozin [94], suggest a whole-body metabolic adaptation following SGLT2 inhibition [95].”
BackgroundResultInfluentialSodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · cited 3×
“The risk of deleterious consequences on muscle metabolism (possible muscle atrophy) during SGLT2 inhibition appears negligible, and weight loss concerns mainly fat mass rather than lean body mass [39, 41, 81].”
BackgroundResultBailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 860
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837 · cited 2×
“ficial effects on glycaemic control [57].”
BackgroundDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · cited 3×
“Another compensatory mechanism concerns endogenous glucose production, which is enhanced and most probably driven by an increased glucagon secretion [28, 94].”
BackgroundCefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698 · cited 2×
“metformin, while the dose of 10 mg/day resulted in a greater HbA1c diminution [31].”
BackgroundKohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652 · cited 6×
“In another study in patients with moderate RI (stage 3 CKD), dapagliflozin did not improve glycaemic control, but nevertheless reduced body weight and blood pressure after 24 weeks (Table 2) [47].”
BackgroundInfluentialStenlöf, K., Cefalu, W. T., Kim, K. ‐., Alba, M., Usiskin, K., Tong, C., Canovatchel, W., & Meininger, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12054 · Cited by 614
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608
[Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
Scheen, A. J., & Mathieu, C. (2012) · PubMed · Cited by 581
Self-citationBarnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Management of type 2 diabetes: new and future developments in treatment
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60207-9 · Cited by 533
Nauck, M. A., Del Prato, S., Meier, J. J., Durán-García, S., Rohwedder, K., Elze, M., & Parikh, S. J. (2011) · Diabetes Care · doi:10.2337/dc11-0606 · Cited by 528
Lavalle-González, F. J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., & Meininger, G. (2013) · Diabetologia · doi:10.1007/s00125-013-3039-1 · Cited by 492
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
Yale, J. ‐., Bakris, G., Cariou, B., Yue, D., David‐Neto, E., Xi, L., Figueroa, K., Wajs, E., Usiskin, K., & Meininger, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12090 · Cited by 487
Bolinder, J., Ljunggren, Ö., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., & Parikh, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12189 · Cited by 482
Schernthaner, G., Gross, J. L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., Kawaguchi, M., Canovatchel, W., & Meininger, G. (2013) · Diabetes Care · doi:10.2337/dc12-2491 · Cited by 480
Wilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., & for the Dapagliflozin 006 Study Group* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00003 · Cited by 467
Baker, W. L., Smyth, L. R., Riche, D. M., Bourret, E. M., Chamberlin, K. W., & White, W. B. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.01.007 · Cited by 452
Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70084-6 · Cited by 450
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443
Rosenstock, J., Aggarwal, N., Polidori, D., Zhao, Y., Arbit, D., Usiskin, K., Capuano, G., Canovatchel, W., & for the Canagliflozin DIA 2001 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1926 · Cited by 421
Rosenstock, J., Vico, M., Wei, L., Salsali, A., & List, J. F. (2012) · Diabetes Care · doi:10.2337/dc11-1693 · Cited by 408
Strojek, K., Yoon, K. H., Hruba, V., Elze, M., Langkilde, A. M., & Parikh, S. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01434.x · Cited by 406
Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA-REG MET Trial Investigators (2014) · Diabetes Care · doi:10.2337/dc13-2105 · Cited by 400
Chino, Y., Samukawa, Y., Sakai, S., Nakai, Y., Yamaguchi, J., Nakanishi, T., & Tamai, I. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1909 · Cited by 389
Kovacs, C. S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA‐REG PIO™ trial investigators (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12188 · Cited by 387
Ridderstråle, M., Andersen, K. R., Zeller, C., Kim, G., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70120-2 · Cited by 378
Vallon, V., & Thomson, S. C. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020911-153333 · Cited by 376
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA-REG METSU Trial Investigators (2013) · Diabetes Care · doi:10.2337/dc12-2673 · Cited by 371
Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H. J., & Broedl, U. C. (2014) · Diabetes Care · doi:10.2337/dc13-3055 · Cited by 363
Bailey, C. J., Gross, J. L., Hennicken, D., Iqbal, N., Mansfield, T. A., & List, J. F. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-43 · Cited by 352
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Nauck, M. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s50773 · Cited by 343
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Stein, P., Desai, M., Shaw, W., Jiang, J., Vercruysse, F., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.007 · Cited by 341
SGLT inhibitors in management of diabetes
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70050-0 · Cited by 332
Wilding, J. P. H., Charpentier, G., Hollander, P., González‐Gálvez, G., Mathieu, C., Vercruysse, F., Usiskin, K., Law, G., Black, S., Canovatchel, W., et al. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12322 · Cited by 317
Henry, R. R., Murray, A. V., Marmolejo, M. H., Hennicken, D., Ptaszynska, A., & List, J. F. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02911.x · Cited by 310
Rieg, T., Masuda, T., Gerasimova, M., Mayoux, E., Platt, K., Powell, D. R., Thomson, S. C., Koepsell, H., & Vallon, V. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00518.2013 · Cited by 310
Sha, S., Devineni, D., Ghosh, A., Polidori, D., Chien, S., Wexler, D., Shalayda, K., Demarest, K., & Rothenberg, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01406.x · Cited by 297
Wilding, J. P. H., Woo, V., Rohwedder, K., Sugg, J., Parikh, S., & for the Dapagliflozin 006 Study Group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12187 · Cited by 291
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.560181 · Cited by 287
Jabbour, S. A., Hardy, E., Sugg, J., Parikh, & for the Study 10 Group (2014) · Diabetes Care · doi:10.2337/dc13-0467 · Cited by 286
Kasichayanula, S., Liu, X., LaCreta, F., Griffen, S. C., & Boulton, D. W. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0104-3 · Cited by 276
Yale, J. ‐., Bakris, G., Cariou, B., Nieto, J., David‐Neto, E., Yue, D., Wajs, E., Figueroa, K., Jiang, J., Law, G., et al. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12348 · Cited by 273
Heise, T., Seewaldt‐Becker, E., Macha, S., Hantel, S., Pinnetti, S., Seman, L., & Woerle, H. J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12073 · Cited by 273
Polidori, D., Sha, S., Mudaliar, S., Ciaraldi, T. P., Ghosh, A., Vaccaro, N., Farrell, K., Rothenberg, P., & Henry, R. R. (2013) · Diabetes Care · doi:10.2337/dc12-2391 · Cited by 261
Forst, T., Guthrie, R., Goldenberg, R., Yee, J., Vijapurkar, U., Meininger, G., & Stein, P. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12273 · Cited by 255
Sha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S. ‐., Sica, D., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12322 · Cited by 249
Zambrowicz, B., Freiman, J., Brown, P. M., Frazier, K. S., Turnage, A., Bronner, J., Ruff, D., Shadoan, M., Banks, P., Mseeh, F., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.58 · Cited by 243
Zinman, B., Inzucchi, S. E., Lachin, J. M., Wanner, C., Ferrari, R., Fitchett, D., Bluhmki, E., Hantel, S., Kempthorne-Rawson, J., Newman, J., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-102 · Cited by 239
Bode, B., Stenlöf, K., Sullivan, D., Fung, A., & Usiskin, K. (2013) · Hospital Practice · doi:10.3810/hp.2013.04.1020 · Cited by 239
Henry, R. R., Rosenstock, J., Edelman, S., Mudaliar, S., Chalamandaris, A.-G., Kasichayanula, S., Bogle, A., Iqbal, N., List, J., & Griffen, S. C. (2015) · Diabetes Care · doi:10.2337/dc13-2955 · Cited by 238
Scheen, A. J. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0126-x · Cited by 234
Self-citationPerkins, B. A., Cherney, D. Z. I., Partridge, H., Soleymanlou, N., Tschirhart, H., Zinman, B., Fagan, N. M., Kaspers, S., Woerle, H.-J., Broedl, U. C., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2338 · Cited by 231
Devineni, D., Morrow, L., Hompesch, M., Skee, D., Vandebosch, A., Murphy, J., Ways, K., & Schwartz, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01558.x · Cited by 220
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysis
Liakos, A., Karagiannis, T., Athanasiadou, E., Sarigianni, M., Mainou, M., Papatheodorou, K., Bekiari, E., & Tsapas, A. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12307 · Cited by 219
Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
Oliva, R. V., & Bakris, G. L. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.02.003 · Cited by 219
Renal glucose reabsorption inhibitors to treat diabetes
Bailey, C. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.011 · Cited by 217
Ljunggren, Ö., Bolinder, J., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., & Parikh, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01630.x · Cited by 215
Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin
Ferrannini, E., Berk, A., Hantel, S., Pinnetti, S., Hach, T., Woerle, H. J., & Broedl, U. C. (2013) · Diabetes Care · doi:10.2337/dc13-0663 · Cited by 214
Rosenstock, J., Seman, L. J., Jelaska, A., Hantel, S., Pinnetti, S., Hach, T., & Woerle, H. J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12185 · Cited by 214
Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin
Johnsson, K. M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S. J., & List, J. F. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.04.012 · Cited by 213
Kaku, K., Watada, H., Iwamoto, Y., Utsunomiya, K., Terauchi, Y., Tobe, K., Tanizawa, Y., Araki, E., Ueda, M., Suganami, H., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-65 · Cited by 212
Urinary tract infections in patients with diabetes treated with dapagliflozin
Johnsson, K. M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S. J., & List, J. F. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.05.004 · Cited by 205
Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
Scheen, A. J., & Van Gaal, L. F. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70004-x · Cited by 190
Self-citationScheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0264-4 · Cited by 182
Self-citationLeiter, L. A., Cefalu, W. T., de Bruin, T. W. A., Gause‐Nilsson, I., Sugg, J., & Parikh, S. J. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12881 · Cited by 182
Ferrannini, E., Seman, L., Seewaldt‐Becker, E., Hantel, S., Pinnetti, S., & Woerle, H. J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12081 · Cited by 181
SGLT2 inhibitors in the treatment of type 2 diabetes
Hasan, F. M., Alsahli, M., & Gerich, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.02.014 · Cited by 173
Ji, L., Ma, J., Li, H., Mansfield, T. A., T’joen, C. L., Iqbal, N., Ptaszynska, A., & List, J. F. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.11.002 · Cited by 172
Neumiller, J. J., White, J. R., & Campbell, R. K. (2010) · Drugs · doi:10.2165/11318680-000000000-00000 · Cited by 170
Bailey, C. J., Iqbal, N., T'joen, C., & List, J. F. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01659.x · Cited by 167
De Nicola, L., Gabbai, F. B., Liberti, M. E., Sagliocca, A., Conte, G., & Minutolo, R. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.02.010 · Cited by 167
Ipragliflozin: First Global Approval
Poole, R. M., & Dungo, R. T. (2014) · Drugs · doi:10.1007/s40265-014-0204-x · Cited by 158
SEMAN, L. J., Macha, S., Nehmiz, G., Simons, G., Ren, B., Pinnetti, S., Woerle, H. J., & Dugi, K. A. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.16 · Cited by 152
Nyirjesy, P., Zhao, Y., Ways, K., & Usiskin, K. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.697053 · Cited by 148
Kurosaki, E., & Ogasawara, H. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.04.003 · Cited by 148
Seino, Y., Sasaki, T., Fukatsu, A., Ubukata, M., Sakai, S., & Samukawa, Y. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.912983 · Cited by 146
Nyirjesy, P., Sobel, J. D., Fung, A., Mayer, C., Capuano, G. A., Ways, K., & Usiskin, K. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.890925 · Cited by 139
Heise, T., SEMAN, L. J., Macha, S., Jones, P., Marquart, A., Pinnetti, S., Woerle, H. J., & Dugi, K. A. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0030-2 · Cited by 137
Kaku, K., Inoue, S., Matsuoka, O., Kiyosue, A., Azuma, H., Hayashi, N., Tokudome, T., Langkilde, A. M., & Parikh, S. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12047 · Cited by 135
Yang, X., Lai, D., Zhong, X., Shen, H., & Huang, Y. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1730-x · Cited by 134
Zhang, M., Zhang, L., Wu, B., Song, H.-L., An, Z., & Li, S. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2479 · Cited by 129
Scheen, A. J., & Paquot, N. (2014) · Diabetes & Metabolism · doi:10.1016/s1262-3636(14)72689-8 · Cited by 125
Self-citationMacha, S., Mattheus, M., Halabi, A., Pinnetti, S., Woerle, H. J., & Broedl, U. C. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12182 · Cited by 125
Inagaki, N., Kondo, K., Yoshinari, T., Takahashi, N., Susuta, Y., & Kuki, H. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.935764 · Cited by 124
Miao, Z., Nucci, G., Amin, N. B., Sharma, R., Mascitti, V., Tugnait, M., Vaz, A. D. N., Callegari, E., & Kalgutkar, A. S. S. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.049551 · Cited by 123
Kasichayanula, S., Liu, X., Benito, M. P., Yao, M., Pfister, M., LaCreta, F. P., Humphreys, W. G., & Boulton, D. W. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12056 · Cited by 121
Effects of Dapagliflozin on Cardiovascular Risk Factors
Ptaszynska, A., Hardy, E., JOHNSSON, E. K., Parikh, S. J., & List, J. F. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2667 · Cited by 120
Wilding, J. P. H., Ferrannini, E., Fonseca, V. A., Wilpshaar, W., Dhanjal, P., & Houzer, A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12038 · Cited by 120
Polidori, D., Mari, A., & Ferrannini, E. (2014) · Diabetologia · doi:10.1007/s00125-014-3196-x · Cited by 117
Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy
Yamout, H., Perkovic, V., Davies, M. J., Woo, V. C., de Zeeuw, D., Mayer, C., Vijapurkar, U., Kline, I., Usiskin, K., Meininger, G. E., et al. (2014) · American Journal of Nephrology · doi:10.1159/000364909 · Cited by 115
Nauck, M. A., Prato, S. D., Durán-Garcia, S., Rohwedder, K., Langkilde, A. M., Sugg, J. E., & Parikh, S. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12327 · Cited by 114
Goring, S. M., Hawkins, N., Wygant, G. D., Roudaut, M., Townsend, R., Wood, I., & Barnett, A. H. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12239 · Cited by 109
Kaku, K., Kiyosue, A., Inoue, S., Ueda, N., Tokudome, T., Yang, J., & Langkilde, A. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12325 · Cited by 108
Kashiwagi, A., Kazuta, K., Goto, K., Yoshida, S., Ueyama, E., & Utsuno, A. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12331 · Cited by 102
Dapagliflozin: A Review of its Use in Type 2 Diabetes Mellitus
Plosker, G. L. (2012) · Drugs · doi:10.2165/11209910-000000000-00000 · Cited by 101
Tofogliflozin: First Global Approval
Poole, R. M., & Prossler, J. E. (2014) · Drugs · doi:10.1007/s40265-014-0229-1 · Cited by 100
Luseogliflozin: First Global Approval
Markham, A., & Elkinson, S. (2014) · Drugs · doi:10.1007/s40265-014-0230-8 · Cited by 99
Kadowaki, T., Haneda, M., Inagaki, N., Terauchi, Y., Taniguchi, A., Koiwai, K., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0126-8 · Cited by 95
Kasichayanula, S., Liu, X., Zhang, W., Pfister, M., LaCreta, F. P., & Boulton, D. W. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.011 · Cited by 94
Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Plosker, G. L. (2014) · Drugs · doi:10.1007/s40265-014-0225-5 · Cited by 93
Scheen, A. J. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0128-8 · Cited by 93
Self-citationSchernthaner, G., Gross, J., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., Kawaguchi, M., Canovatchel, W. J., & Meininger, G. E. (2013) · Diabetes Care · doi:10.2337/dc13-er12a · Cited by 93
Fonseca, V. A., Ferrannini, E., Wilding, J. P. H., Wilpshaar, W., Dhanjal, P., Ball, G., & Klasen, S. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.11.005 · Cited by 91
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.777428 · Cited by 91
Self-citationCardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes
Scheen, A. J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2659 · Cited by 90
Self-citationGraham‐Pole, J. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-8-199404150-00013 · Cited by 86
Berhan, A., & Barker, A. J. (2013) · BMC Endocrine Disorders · doi:10.1186/1472-6823-13-58 · Cited by 86
Sinclair, A. J., Bode, B. W., Harris, S. B., Vijapurkar, U., Mayer, C., Fung, A., Shaw, W. C., Usiskin, K., Desai, M. G., & Meininger, G. E. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-37 · Cited by 85
Sun, Y.-N., Zhou, Y., Chen, X., Che, W.-S., & Leung, S.-W. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004619 · Cited by 83
Canagliflozin: First Global Approval
Elkinson, S., & Scott, L. J. (2013) · Drugs · doi:10.1007/s40265-013-0064-9 · Cited by 82
Strojek, K., Yoon, K., Hrubá, V., Sugg, J. E., Langkilde, A. M., & Parikh, S. J. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0072-0 · Cited by 82
Ferrannini, E., Veltkamp, S. A., Smulders, R. A., & Kadokura, T. (2013) · Diabetes Care · doi:10.2337/dc12-1503 · Cited by 81
Dobbins, R. L., O’Connor‐Semmes, R., Kapur, A., Kapitza, C., Golor, G., Mikoshiba, I., Tao, W., & Hussey, E. K. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01462.x · Cited by 80
Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations
Scheen, A. J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.873788 · Cited by 79
Self-citationNicolle, L. E., Capuano, G. A., Ways, K., & Usiskin, K. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.689956 · Cited by 79
Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal
Scheen, A. J., & Charbonnel, B. H. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.03.004 · Cited by 76
Self-citationEffects of SGLT2 inhibitors on cardiovascular outcomes
Foote, C., Perkovic, V., & Neal, B. C. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441190 · Cited by 76
Macha, S., Rose, P. W., Mattheus, M., Cinca, R., Pinnetti, S., Broedl, U. C., & Woerle, H. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12183 · Cited by 73
Schwartz, S. L., Akinlade, B., Klasen, S., Kowalski, D. L., Zhang, W., & Wilpshaar, W. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0012 · Cited by 70
Friedrich, C., Metzmann, K., Rose, P. W., Mattheus, M., Pinnetti, S., & Woerle, H. J. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.12.002 · Cited by 68
Lamos, E. M., Younk, L. M., & Davis, S. N. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.791282 · Cited by 65
Zambrowicz, B., Ogbaa, I., Frazier, K., Banks, P. L., Turnage, A., Freiman, J. P., Boehm, K. A., Ruff, D. A., Powell, D. R., & Sands, A. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.06.011 · Cited by 64
Seino, Y., Sasaki, T., Fukatsu, A., Sakai, S., & Samukawa, Y. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.901943 · Cited by 64
Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0298-1 · Cited by 64
Stanton, R. C. (2013) · Circulation · doi:10.1161/circulationaha.113.007071 · Cited by 62
Seino, Y., Sasaki, T., Fukatsu, A., Ubukata, M., Sakai, S., & Samukawa, Y. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.909390 · Cited by 61
Veltkamp, S. A., Kadokura, T., Krauwinkel, W. J. J., & Smulders, R. A. (2011) · Clinical Drug Investigation · doi:10.1007/bf03256922 · Cited by 55
Basile, J. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.12.004 · Cited by 48
Furuse, K. (1995) · PubMed · Cited by 48
Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition
Cefalu, W. T. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74297 · Cited by 46
Grandy, S., Hashemi, M., Langkilde, A., Parikh, S. J., & Sjöström, C. D. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12263 · Cited by 45
Barnett, A. H. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.09.2698 · Cited by 44
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
Lamos, E. M., Younk, L. M., & Davis, S. N. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.909407 · Cited by 43
Ridderstråle, M., Svärd, R., Zeller, C., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-129 · Cited by 41
Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus
Asche, C. V., Hippler, S. E., & Eurich, D. T. (2013) · PharmacoEconomics · doi:10.1007/s40273-013-0117-7 · Cited by 36
A Review of the Efficacy and Safety of Canagliflozin in Elderly Patients with Type 2 Diabetes
Elmore, L. K., Baggett, S., Kyle, J. A., & Skelley, J. W. (2014) · The Consultant Pharmacist · doi:10.4140/tcp.n.2014.335 · Cited by 36
Sasaki, T., Seino, Y., Fukatsu, A., Sakai, S., & Samukawa, Y. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0102-3 · Cited by 35
Sykes, A. P., Kemp, G. L., Dobbins, R. L., O’Connor‐Semmes, R., Almond, S., Wilkison, W. O., Walker, S., & Kler, L. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12393 · Cited by 35
Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin
Kadokura, T., Zhang, W., Krauwinkel, W. J. J., Leeflang, S., Keirns, J. J., Taniuchi, Y., Nakajo, I., & Smulders, R. A. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0180-z · Cited by 33
Qiu, R., Capuano, G. A., & Meininger, G. E. (2014) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2014.04.001 · Cited by 32
Traina, S., Guthrie, R. M., & Slee, A. E. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2752 · Cited by 28
Veltkamp, S. A., van Dijk, J., Collins, C., van Bruijnsvoort, M., Kadokura, T., & Smulders, R. A. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.06.027 · Cited by 23
SGLT2 versus DPP4 inhibitors for type 2 diabetes
Scheen, A. J. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70095-0 · Cited by 23
Self-citationSafety of Canagliflozin in Patients with Type 2 Diabetes
Mikhail, N. E. (2014) · Current Drug Safety · doi:10.2174/1574886309666140120100255 · Cited by 22
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Bailey, R. A., Damaraju, C. V., Martin, S. C., Meininger, G. E., Rupnow, M. F. T., & Blonde, L. (2014) · PubMed · Cited by 19
Bell, D. S. H. (2014) · American Journal of Case Reports · doi:10.12659/ajcr.890626 · Cited by 14
Engeli, S., & Jordan, J. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0374-z · Cited by 12
Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
Brooks, A. D., Salvo, M. C., & Thacker, S. M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s59169 · Cited by 8
Bonnet, F., & Scheen, A. J. (2014) · Diabetes & Metabolism · doi:10.1016/s1262-3636(14)72688-6 · Cited by 6
Self-citation
Cited by
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M. R., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 784
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 553
Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship
Mesinovic, J., Zengin, A., De Courten, B., Ebeling, P. R., & Scott, D. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s186600 · Cited by 553
Metadata
- Authors
- Scheen, A. J.
- Venue
- Drugs
- Published
- 2014-12-09
- Volume
- 75
- Issue
- 1
- Pages
- 33-59
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W1973038508
- Cited by
- 554
- References
- 156
- FWCI
- 31.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.